Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Fig. 4

Mean change from baseline in monthly average number of days with any acute headache medication use. a, b CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMD

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us